Arvinas (NASDAQ:ARVN) Hits New 52-Week Low - Should You Sell?

Arvinas, Inc. (NASDAQ:ARVN) has recently hit a new 52-week low, reaching $7.83 during trading on Thursday, before closing at $7.85. This is a notable drop from its previous closing price of $7.95, with a trading volume of 677,217 shares.

Wall Street Analysts Forecast Growth

Recent analyst reports have brought attention to ARVN. Guggenheim revised its target price for Arvinas, reducing it from $57.00 to $32.00 while maintaining a "buy" rating on the stock. Barclays also lowered its price objective from $48.00 to $32.00, giving the company an "overweight" rating. Oppenheimer downgraded Arvinas from an "outperform" to a "market perform" rating. In a similar move, Bank of America decreased its price target from $54.00 to $28.00, also setting a "buy" rating. Lastly, BMO Capital Markets established a target price of $20.00 with an "outperform" rating. Currently, five analysts suggest holding the stock, while ten recommend buying it, leading to an average rating of "Moderate Buy" and a consensus price target of $35.50 as reported by MarketBeat.

Arvinas Price Performance

The stock has a 50-day moving average of $15.67 and a 200-day moving average of $20.91, indicating a struggling trend. With a market capitalization of $549.49 million, Arvinas has a P/E ratio of -2.87 and a beta of 1.95. Its last earnings report was released on February 11, where the company posted earnings per share (EPS) of ($0.63), which surpassed analysts’ expectation of ($1.07) by $0.44. However, the company exhibited a negative net margin of 75.51% and a return on equity of -33.75%. Analysts are predicting that Arvinas will report a -3.81 EPS for the current fiscal year.

Insider Buying and Selling at Arvinas

Recent insider transactions have shown active trading. For instance, insider Ian Taylor sold 9,020 shares on February 24 at an average price of $16.71, totaling around $150,724.20. After this sale, he retains ownership of 159,121 shares in the company. Similarly, CEO John G. Houston sold 31,338 shares on the same day for about $523,971.36. Following this sale, Houston holds approximately 1,157,480 shares in Arvinas. Over the last quarter, insiders sold 50,230 shares valued at approximately $769,402, with 5.23% of the stock currently held by insiders.

Institutional Trading of Arvinas

Institutional investors have recently bought and sold shares of Arvinas, impacting its stock performance. For example, GF Fund Management acquired a new stake worth approximately $28,000 in the fourth quarter. KBC Group NV increased its holdings by 77%, owning a total of 2,885 shares valued at $55,000 after purchasing an additional 1,255 shares. Moreover, Quantbot Technologies raised its stake by 147.3% during the third quarter, owning 4,367 shares valued at $108,000. Overall, institutional and hedge fund investments constitute 95.19% of the company's shares.

About Arvinas

Arvinas, Inc. is a clinical-stage biotechnology firm dedicated to developing and commercializing therapies that degrade disease-causing proteins. The company utilizes innovative techniques to create proteolysis targeting chimeras (PROTAC), which are designed to leverage the body's natural protein disposal mechanisms to eliminate harmful proteins.

Arvinas, Stocks, Investing